DIFFERENTIAL INTERACTION OF THE OPIOID RECEPTOR WITH AGONIST AND ANTAGONIST MORPHINAN DERIVATIVES

被引：0
|
作者：
LEMAIRE, S
BELLEAU, B
机构：
[1] UNIV OTTAWA, FAC HLTH SCI, DEPT PHARMACOL, OTTAWA K1N 6N5, ONTARIO, CANADA
[2] MCGILL UNIV, DEPT CHEM, MONTREAL H3A 2T5, QUEBEC, CANADA
来源：
FASEB JOURNAL | 1988年 / 2卷 / 05期
关键词：
D O I：
暂无
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
引用
收藏
页码：A1391 / A1391
页数：1
相关论文
共 50 条
  • [21] Effect of the tyramine fragment of opioid receptor ligands on their agonist and antagonist properties
    Kuz'mina N.E.
    Osipova E.S.
    Kuz'min V.S.
    Sitnikov V.B.
    Pharmaceutical Chemistry Journal, 2006, 40 (5) : 254 - 260
  • [22] Effects of kappa opioid receptor agonist and antagonist on the aversive effects of nicotine
    DSouza, Manoranjan S.
    Ward, Melissa
    Norman, Haval
    FASEB JOURNAL, 2016, 30
  • [23] Structural Determinants for the Binding of Morphinan Agonists to the μ-Opioid Receptor
    Cong, Xiaojing
    Campomanes, Pablo
    Kless, Achim
    Schapitz, Inga
    Wagener, Markus
    Koch, Thomas
    Carloni, Paolo
    PLOS ONE, 2015, 10 (08):
  • [24] Development of bifunctional mu opioid receptor (MOR) agonist/delta opioid receptor (DOR) antagonist peptides and peptidomimetics
    Mosberg, Henry I.
    Anand, Jessica
    Bender, Aaron
    Harland, Aubrie A.
    Sobczyk-Kojiro, Katarzyna
    Yeomans, Larisa
    Jutkiewicz, Emily M.
    Traynor, John
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2014, 248
  • [25] Opioid Peptidomimetics: Leads for the Design of Bioavailable Mixed Efficacy μ Opioid Receptor (MOR) Agonist/δ Opioid Receptor (DOR) Antagonist Ligands
    Mosberg, Henry I.
    Yeomans, Larisa
    Harland, Aubrie A.
    Bender, Aaron M.
    Sobczyk-Kojiro, Katarzyna
    Anand, Jessica P.
    Clark, Mary J.
    Jutkiewicz, Emily M.
    Traynor, John R.
    JOURNAL OF MEDICINAL CHEMISTRY, 2013, 56 (05) : 2139 - 2149
  • [26] Abuse Potential and Pharmacodynamic Characteristics of Oral and Intranasal Eluxadoline, a Mixed μ- and κ-Opioid Receptor Agonist and δ-Opioid Receptor Antagonist
    Levy-Cooperman, N.
    McIntyre, G.
    Bonifacio, L.
    McDonnell, M.
    Davenport, J. M.
    Covington, P. S.
    Dove, L. S.
    Sellers, E. M.
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2016, 359 (03): : 471 - 481
  • [27] Longitudinal Measurement of Opioid Receptor Occupancy from Sustained Release Naltrexone: Comparison of Agonist, Partial Agonist and Antagonist Opioid Receptor Radiotracers in Rats
    Reed, B.
    Schoultz, B.
    Coello, C.
    Hjornevik, T.
    Lindblom, I.
    Henriksen, G.
    Willoch, F.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2012, 39 : S266 - S266
  • [28] DIFFERENTIAL ORIENTATION OF A GNRH AGONIST AND ANTAGONIST IN THE PITUITARY GNRH RECEPTOR
    JANOVICK, JA
    HAVIV, F
    FITZPATRICK, TD
    CONN, PM
    ENDOCRINOLOGY, 1993, 133 (02) : 942 - 945
  • [29] Differential effects of opioid receptors agonist and antagonist on hippocampal seizure in-vitro
    Balakhani, ED
    Dodangeh, E
    Derchansky, M
    El-Beheiry, H
    Jahromi, SS
    Carlen, PL
    EPILEPSIA, 2005, 46 : 371 - 371
  • [30] Differential agonist regulation of the human kappa-opioid receptor
    Blake, AD
    Bot, G
    Li, SX
    Freeman, JC
    Reisine, T
    JOURNAL OF NEUROCHEMISTRY, 1997, 68 (05) : 1846 - 1852
12345